Gout and risk of Parkinson disease: A prospective study

Neurology

Volumn 69, Issue 17, 2007, Pages 1696-1700

  Alonso, Alvaro ^a,c   Rodríguez, Luis A García ^b   Logroscino, Giancarlo ^a   Hernán, Miguel A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Pharmacoepidemiology   (Spain)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; FACTUAL DATABASE; RISK FACTOR;

CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; GOUT; HUMANS; MALE; PARKINSON DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 36048943239     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000279518.10072.df     Document Type: Article

References (30)

1. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005;14:2749-2755.
2. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53 (suppl 3):S26-S38.
3. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80: 101-110.
4. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419-425.
5. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480-484.
6. de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797-800.
7. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
8. Larumbe Ilundáin R, Ferrer Valls JV, Viñes Rueda JJ, Guerrero D, Fraile P. [Case-control study of oxidative stress and plasma iron metabolism markers in Parkinson's disease.] Rev Esp Salud Publica 2001;75:43-54.
9. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-345.
10. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003;23:686-689.
11. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
12. Hernán MA, Logroscino G, García-Rodríguez LA.. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004;251:vii14-vii17.
13. Hernán MA, Logroscino G, García-Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson's disease. Neurology 2006;66:1097-1099.
14. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997; 44:175-178.
15. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990 - 1999. Ann Rheum Dis 2005;64:267-272.
16. Hernán MA, Robins JM, García-Rodríguez LA. Statistical issues arising in the Women's Health Initiative - Discussion. Biometrics 2005;61:922-930.
17. Hernán MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
18. Kiyohara C, Kono S, Honjo S, et al. Inverse association between coffee drinking and serum uric acid concentrations in middle-aged Japanese males. Br J Nutr 1999; 82:125-130.
19. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate level predicts progression of Parkinson's disease. In: 36th annual meeting of the Society for Neuroscience; 2006; Atlanta, GA. Abstract #510.
20. Ascherio A, LeWitt PA, Watts A, et al. CSF as well as serum urate are predictors of Parkinson's disease progression. In: 10th International Conference of Parkinson's Disease and Movement Disorders; 2006; Kyoto, Japan. LB-2.
21. Hooper DC, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1997;94:2528-2533.
22. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 2005;102:3483-3488.
23. Iravani MM, Haddon CO, Rose S, Jenner P. 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 2006; 1067:256-262.
24. Anderson RF, Harris TA. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. Free Radic Res 2003;37: 1131-1136.
25. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
26. de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998-1002.
27. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000;27:1045-1050.
28. Duthie GG, Arthur JR, James WPT.. Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 1991;53:1061S-1063S.
29. Lellouch J, Schwartz D, Tran MH, Beaumont JL. The relationships between smoking and levels of serum urea and uric acid. Results from an epidemiological survey. J Chron Dis 1969;22:9-15.
30. Nakanishi N, Tatara K, Nakamura K, Suzuki K. Risk factors for the incidence of hyperuricemia: a 6-year longitudinal study of middle-aged Japanese men. Int J Epidemiol 1999;28:888-893.